Matrixx unveils 2009 launches
This article was originally published in The Tan Sheet
Executive Summary
Xcid antacid product will debut early in fiscal year 2009, and will be positioned as a better tasting product than competing antacids, the Zicam marketer announces. "Consumers perceive liquid antacid products to be highly efficacious, but they taste very bad," Matrixx President and CEO Carl Johnson notes. Xcid will come in three 'soother' flavors: Milk Chocolate, Creamy Orange and Creamy Strawberry. Products will be sold in squeezable tubes and labels will feature the statement: "from the makers of Zicam." The formula contains maximum strength ingredients calcium carbonate and magnesium hydroxide, firm notes. Matrixx also will launch Zicare, the first OTC oral care product designed to dissolve tartar, in early 2008, according to Johnson. The cinnamon-flavored adhesive gel is applied to teeth after brushing. In developing the product over the past 18 months, the company has filed seven patents and conducted clinical trials. The product will be distributed in dental offices before rolling out to retailers in coming years, the company says...
You may also be interested in...
Slow Launch Of Xcid Antacid Spurs Matrixx To Marketing Changes
Matrixx Initiatives plans product-sampling and coupon-marketing activities as well as store displays in response to "small" sales of its latest product, Xcid antacid, the firm says
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.